OPKO Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OPKO Health, Inc. on August 13, 2026. The filing discloses the entry into a material definitive agreement involving the issuance of additional senior secured notes.
Key Financial Metrics and Debt Structure
- Debt Issuance: The Company issued Additional Notes with an aggregate initial principal amount of $125,000,000.
- Interest Rate: Notes bear interest at the 3-month Secured Overnight Financing Rate (SOFR) subject to a 4.0% per annum floor, plus 7.5% per annum.
- Maturity Date: July 17, 2044.
- Collateral: Notes are secured by EirGen Pharma Limited's royalty interest in mazdutide under a license agreement with Eli Lilly and Company (Mazdutide Payments) and profit share payments from Pfizer, Inc. (Royalty Payments).
- Payment Mechanism: Interest is payable quarterly based on Royalty Payments. If Royalty Payments are insufficient, Mazdutide Payments cover the excess interest. Any remaining Mazdutide Payments are used to pay down principal.
- Caps: Mazdutide Payments applied to the notes are capped at $187.5 million.
Material Changes
The filing represents an amendment to the Note Purchase Agreement originally dated July 17, 2024. The primary material change is the increase in total indebtedness through the issuance of the $125 million in Additional Notes. The terms of the existing notes remain unchanged.
Guidance, Risks, and Covenants
- Covenants: The Amended Agreement includes negative covenants limiting indebtedness, liens, amendments to material contracts, and asset dispositions. It also contains financial covenants and customary events of default.
- Risks: Repayment obligations are contingent on royalty and profit share receipts from third parties (Pfizer and Eli Lilly). Default events include payment non-compliance, bankruptcy, and cross-payment defaults.
- Regulatory Status: The issuance relied on exemptions from registration under Section 4(a)(2) of the Securities Act and Rule 144, sold to accredited investors or qualified institutional buyers.
Investor Verification Checklist
- Verify the full text of the Amended Agreement and Additional Note form, which will be filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2026.
- Confirm the current status of Royalty Payments from Pfizer and Mazdutide Payments from Eli Lilly to assess immediate interest coverage.
- Review the specific financial covenants and negative covenants to understand operational restrictions.
- Assess the total outstanding principal under the Notes following this $125 million issuance.